StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)

Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –

Neurocrine Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Neurocrine Biosciences's profit margin for the twelve months ending Jun 30, 2026 was 20.9%. For fiscal 2025 it was 16.7%, against 14.5% the year before. The highest annual figure on record is 48.5% in fiscal 2011.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202516.7%+2.2
FY2024Dec 31, 202414.5%+1.3
FY2023Dec 31, 202313.2%+2.9
FY2022Dec 31, 202210.4%+2.5
FY2021Dec 31, 20217.9%−31.0
FY2020Dec 31, 202038.9%+34.2
FY2019Dec 31, 20194.7%+0.0
FY2018Dec 31, 20184.7%+92.9
FY2017Dec 31, 2017-88.2%+852.4
FY2016Dec 31, 2016-940.6%−490.8
FY2015Dec 31, 2015-449.8%+1129.1
FY2013Dec 31, 2013-1579.0%−1588.4
FY2012Dec 31, 20129.5%−39.1
FY2011Dec 31, 201148.5%+72.3
FY2010Dec 31, 2010-23.8%+1704.6
FY2009Dec 31, 2009-1728.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202615.1%−0.6
Q1 FY2026Mar 31, 202624.3%+22.9
Q4 FY2025Dec 31, 202519.1%+2.7
Q3 FY2025Sep 30, 202526.4%+5.5
Q2 FY2025Jun 30, 202515.6%+4.6
Q1 FY2025Mar 31, 20251.4%−7.0
Q4 FY2024Dec 31, 202416.4%−12.2
Q3 FY2024Sep 30, 202420.9%+4.2
Q2 FY2024Jun 30, 202411.0%−10.1
Q1 FY2024Mar 31, 20248.4%+26.6
Q4 FY2023Dec 31, 202328.7%+7.1
Q3 FY2023Sep 30, 202316.7%−1.0
Q2 FY2023Jun 30, 202321.1%+25.6
Q1 FY2023Mar 31, 2023-18.2%−22.7
Q4 FY2022Dec 31, 202221.6%+23.9
Q3 FY2022Sep 30, 202217.7%+10.1
Q2 FY2022Jun 30, 2022-4.5%−19.1
Q1 FY2022Mar 31, 20224.5%−9.1
Q4 FY2021Dec 31, 2021-2.3%−142.7
Q3 FY2021Sep 30, 20217.6%+29.9
Q2 FY2021Jun 30, 202114.6%−11.7
Q1 FY2021Mar 31, 202113.6%−2.2
Q4 FY2020Dec 31, 2020140.3%+126.4
Q3 FY2020Sep 30, 2020-22.3%−46.5
Q2 FY2020Jun 30, 202026.3%−1.6
Q1 FY2020Mar 31, 202015.8%+89.5
Q4 FY2019Dec 31, 201913.9%+0.2
Q3 FY2019Sep 30, 201924.2%−9.2
Q2 FY2019Jun 30, 201928.0%+34.1
Q1 FY2019Mar 31, 2019-73.8%−14.9
Q4 FY2018Dec 31, 201813.7%+6.5
Q3 FY2018Sep 30, 201833.5%+51.8
Q2 FY2018Jun 30, 2018-6.1%+940.8
Q1 FY2018Mar 31, 2018-58.8%–
Q4 FY2017Dec 31, 20177.3%–
Q3 FY2017Sep 30, 2017-18.3%–
Q2 FY2017Jun 30, 2017-946.9%–

More Neurocrine Biosciences figures

See a number that looks wrong?